Shionogi Cash Flow from Operating Activities 2021-2024 | SGIOY

Shionogi cash flow from operating activities for the twelve months ending December 31, 2024 was $0.922B, a 31.44% decline year-over-year.

  • Shionogi annual cash flow from operating activities for 2024 was $1.065B, a 19.12% decline from 2023.
  • Shionogi annual cash flow from operating activities for 2023 was $1.316B, a 44.89% increase from 2022.
  • Shionogi annual cash flow from operating activities for 2022 was $0.908B, a 11.37% decline from 2021.

Shionogi Cash Flow from Operating Activities 2021-2024 | SGIOY

  • Shionogi annual cash flow from operating activities for 2024 was $1.065B, a 19.12% decline from 2023.
  • Shionogi annual cash flow from operating activities for 2023 was $1.316B, a 44.89% increase from 2022.
  • Shionogi annual cash flow from operating activities for 2022 was $0.908B, a 11.37% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$80.2B
Zoetis (ZTS)$68.3B
Daiichi Sankyo, - (DSNKY)$47.1B
Takeda Pharmaceutical (TAK)$46.9B
BeOne Medicines - (ONC)$32.3B
Sandoz Group AG (SDZNY)$26.4B
Summit Therapeutics (SMMT)$20.8B
Merck (MKKGY)$17.3B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.9B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.3B
Madrigal Pharmaceuticals (MDGL)$6.8B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
Procaps Group, S.A (PROCF)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B